Australia Diabetes Drugs Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia diabetes drugs market is expanding on volume and mix rather than on price. A large treated population, newer drug classes and a tightly managed subsidy scheme are shifting spend towards incretin injectables, while older oral classes face generic pressure.

Three forces are shaping the market: a population count now estimated above 2 million, which widens the treatable pool; strict PBS rules that limit subsidised incretin access to type 2 diabetes; and supply recovery, with Novo Nordisk telling the TGA in July 2025 that Ozempic stocks had recovered enough for new patients.

In April 2025 the PBS widened Jardiance access to more than 115,000 additional Australians. In March 2026 the PBAC recommended tirzepatide for type 2 diabetes, yet Eli Lilly declined the listing in April 2026, leaving about 450,000 patients without that option.

Key Market Trends and Insights

• Larger patient pool: A University of Sydney-led study reported in April 2025 that more than 2 million Australians may have diabetes, up to 35% above earlier register-based counts.
• Incretin demand beyond diabetes: A UNSW study published in July 2026 found about half a million Australians regularly use incretin medicines, with 43.8% of units sold privately by April 2025.
• Cheaper oral access: The general PBS co-payment fell from AUD 30 to AUD 25 on 1 January 2026, and the government expects savings above AUD 200 million a year.
• Tirzepatide access stalled: Eli Lilly refused PBS listing on 29 April 2026, calling the government price offer unviable, which affects roughly 450,000 Australians with type 2 diabetes.

Australia Diabetes Drugs Market Size and Forecast

The market is moving from older oral agents and basal insulins towards incretin therapies and cardio-renal protective classes, supported by subsidy changes and new pen devices. Incretin injectables lead in value, while metformin and other generics keep very large patient numbers at low cost. Prefilled injectable pens and online and telehealth pharmacies advance fastest, and community pharmacies remain the main dispensing point. New South Wales remains the largest region, and Queensland grows quickest on population inflow. Subsidy reviews, patent disputes and sponsor pricing negotiations point to a durable change in product mix rather than a short cyclical uplift, even as generic dapagliflozin and sitagliptin gradually pull down average prices in oral classes.

Key Takeaways: Australia Diabetes Drugs Market

Large Treated Population Anchors Long-Term Demand

Revenue is on course to expand by about 63% across the decade, from AUD 1,385.00 million in 2025 to AUD 2,256.02 million in 2035 at a 5.0% CAGR. An estimated 2 million Australians with diabetes, many missing from the national register, keep prescription volumes rising steadily.

Incretin and Pen-Based Products Lead Growth

Oral classes hold a large patient base, but GLP-1 and GIP Receptor Agonists grow at an estimated 7.2% CAGR and Prefilled Injectable Pens at an estimated 6.4% CAGR through 2035. Novo Nordisk restored Ozempic supply in July 2025 and introduced a new 3 mL pen.

Subsidy Decisions Now Set the Pace of Access

PBS listing outcomes, not clinical approval, decide how fast new therapies reach patients, and 2026 showed both sides of that dynamic. Sponsors and the government are negotiating prices while generic entrants challenge established brands.

• PBAC recommended tirzepatide for type 2 diabetes in March 2026
• Eli Lilly declined PBS listing on 29 April 2026
• The Federal Court blocked two generic dapagliflozin products in February 2026

Australia Diabetes Drugs Market Report Summary

Key Insight

Demand is shifting towards incretin therapies and cheaper oral classes as a large treated population meets tighter subsidy rules. New South Wales leads, and Queensland grows fastest.

Key Trends in the Australia Diabetes Drugs Market

The Australia diabetes drugs market is being reshaped by private incretin use, subsidy price cuts, sponsor disputes over listing and the recovery of constrained supply.

July 2026 - UNSW Study Finds Half a Million Australians Regularly Use Incretin Medicines

• UNSW Sydney published the study on 31 July 2026 in the British Journal of Clinical Pharmacology, led by Associate Professor Michael Falster.
• Private access grew to 43.8% of estimated use by April 2025, and nearly half of users paid about AUD 200 to AUD 700 for non-diabetes uses.
• Heavy private demand tightens supply for subsidised patients and gives telehealth channels a clear growth opportunity.

April 2026 - Eli Lilly Declines PBS Listing for Mounjaro in Type 2 Diabetes

• The Limbic reported on 29 April 2026 that Lilly called the government price offer unrealistic and unviable, citing lower reimbursed prices abroad.
• About 450,000 Australians with type 2 diabetes were affected by the decision, according to the same report.
• Lilly warned that without broader PBS change, tirzepatide access will keep depending on the ability to pay.

January 2026 - PBS General Co-payment Falls to AUD 25, Lowering Costs for Empagliflozin and Dapagliflozin

• Diabetes Australia reported on 29 July 2025 that the general co-payment would fall from AUD 30 to AUD 25 from 1 January 2026.
• Jardiance, Glyxambi, Jardiamet, Forxiga, Qtern and Xigduo XR are among the affected medicines.
• Concession card holders are unaffected, as their maximum remains frozen at AUD 7.70 until 2030.

July 2025 - Novo Nordisk Confirms Ozempic Supply Has Recovered for New Patients

• Diabetes Australia reported on 23 July 2025 that Novo Nordisk told the TGA national stocks had recovered enough to prescribe to new patients.
• A new 3 mL pen is replacing the earlier 1.5 mL pre-filled pen for the 0.25 mg and 0.5 mg doses.
• Restored supply removes a major constraint on subsidised incretin growth that held back new starts.

Key Insight

Subsidy design, supply recovery and spreading private use of incretin medicines are the main structural forces, while pricing disputes with sponsors remain the main risk to access.

Recent Market Developments in the Australia Diabetes Drugs Market

Recent developments, presented from the most recent, show the government response to the diabetes inquiry, a tirzepatide recommendation, a generic patent dispute and a wider empagliflozin listing.

May 2026 - Government Backs Wider GLP-1 Eligibility in Response to Diabetes Inquiry

• Diabetes Australia reported on 13 May 2026 that the government gave in-principle support to wider eligibility for incretin medicines.
• The Budget also lifted Medical Research Future Fund investment to AUD 1 billion by 2030, according to the Australian Diabetes Society.
• Policy support for wider access may widen the treated pool, though some recommendations were only noted.

March 2026 - PBAC Recommends Tirzepatide for Adults with Inadequately Controlled Type 2 Diabetes

• The PBS medicine status record shows the committee met on 11 March 2026 and found the 10 mg and 15 mg strengths cost-effective.
• The 5 mg strength was recommended at a reduced price, after an earlier rejection in July 2025.
• The sponsor has since advised it is not proceeding with listing at this time.

February 2026 - Federal Court Grants AstraZeneca Injunction Against Pharmacor Dapagliflozin Generics

• AAP reported that Justice Kylie Downes found AstraZeneca's infringement case strong, blocking two Pharmacor products from sale and PBS listing.
• The listings had been expected to take effect from 1 April 2026, and the trial was listed to begin on 31 August 2026.
• Delayed generic entry protects Forxiga revenue for now, though the dispute signals future price erosion.

April 2025 - PBS Widens Jardiance Access for High-Risk Type 2 Diabetes Patients

• Pharmacy Daily reported on 2 April 2025 that Jardiance 10 mg and 25 mg can start alongside metformin regardless of HbA1c in eligible patients.
• Eligible groups include those at high cardiovascular risk, with existing cardiovascular disease, or who are Aboriginal or Torres Strait Islander.
• More than 115,000 additional Australians became eligible, a direct boost to SGLT2 inhibitor volumes.

Key Insight

Tirzepatide's stalled listing, a patent injunction on a dapagliflozin generic and a government response to the diabetes inquiry show how policy and litigation now shape access and pricing.

Australia Diabetes Drugs Industry Segmentation

The Expert Market Research’s report on the Australia Diabetes Drugs Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Drug Class

• GLP-1 and GIP Receptor Agonists
• SGLT2 Inhibitors
• Insulins
• DPP-4 Inhibitors
• Metformin and Other Oral Agents
• Others

GLP-1 and GIP Receptor Agonists lead on value, in our estimate, and grow fastest at an estimated 7.2% CAGR through 2035, as Ozempic supply recovered in July 2025 and the PBAC backed tirzepatide in March 2026. SGLT2 Inhibitors grow at about 3.2%, helped by the AUD 25 co-payment from January 2026 and Jardiance access widened in April 2025. Insulins grow near 2.0% on steady type 1 and advanced type 2 demand. DPP-4 Inhibitors are broadly flat. Metformin and Other Oral Agents hold the largest patient numbers at very low cost per script.

Market Breakup by Dosage Form

• Prefilled Injectable Pens
• Oral Tablets
• Vials and Cartridges
• Others

Prefilled Injectable Pens lead and grow fastest at an estimated 6.4% CAGR through 2035, in our estimate, because semaglutide, insulin and other incretin products use pen devices, including Novo Nordisk's new 3 mL Ozempic pen of July 2025. Oral Tablets cover metformin, SGLT2 and DPP-4 products and grow near 2.0% as generics gain share. Vials and Cartridges grow slowly, shown by Mounjaro vial unavailability until 31 August 2025 pushing users towards the KwikPen. Others include pump insulin and infusion products.

Market Breakup by Distribution Channel

• Community Pharmacies
• Hospital Pharmacies
• Online and Telehealth Pharmacies
• Others

Community Pharmacies lead, in our estimate, because most PBS scripts are filled there and the AUD 25 general co-payment from January 2026 lowers the patient cost at the counter. Hospital Pharmacies grow at about 4.8%, supported by discharge scripts and specialist initiation. Online and Telehealth Pharmacies grow fastest at an estimated 7.0% CAGR through 2035, as the UNSW study of July 2026 found private use reached 43.8% of incretin units by April 2025. Others include dispensing doctors and remote-area aid posts.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• Others

New South Wales dominates, in our estimate, as the Australian Bureau of Statistics counted 8.67 million residents at 31 March 2026, the largest state population, and it grows at an estimated 4.7% CAGR through 2035 from a large, mature base. Queensland is the fastest-growing region at an estimated 5.6%, on population inflow, with 5.74 million residents. Victoria grows at 4.8% from 7.15 million residents. Western Australia grows at 5.3% from 3.10 million. Others, covering four smaller jurisdictions that together hold about 3.26 million people, grow at 4.7%.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Diabetes Drugs Market

Competition combines global originator sponsors, generic suppliers and local distributors. Entry barriers include PBS listing and pricing negotiations, patent position, cold-chain pen supply, and prescriber and pharmacist relationships across community, hospital and online channels.

Novo Nordisk

Novo Nordisk, headquartered in Bagsvaerd, Denmark, sells Ozempic (semaglutide) and Wegovy in Australia through Novo Nordisk Pharmaceuticals. The PBS record shows a new Ozempic listing for type 2 diabetes finalised on 1 June 2025. In July 2025 the company told the TGA that stocks had recovered for new patients, and its Wegovy proposal for adults with cardiovascular disease and obesity was recommended by the PBAC in November 2025.

Eli Lilly and Company

Eli Lilly and Company, headquartered in Indianapolis, United States, sells Mounjaro (tirzepatide) and Trulicity in Australia and co-markets Jardiance with Boehringer Ingelheim. Mounjaro vials were unavailable until 31 August 2025, according to the TGA. The PBAC recommended tirzepatide for type 2 diabetes in March 2026, but Lilly declined the listing on 29 April 2026, citing an unviable price offer.

AstraZeneca

AstraZeneca, headquartered in Cambridge, United Kingdom, sells Forxiga (dapagliflozin) and the combinations Qtern and Xigduo XR in Australia for type 2 diabetes, heart failure and kidney disease. In February 2026 the Federal Court granted it an injunction preventing Pharmacor from selling two generic dapagliflozin products or listing them on the PBS, with the trial listed to begin on 31 August 2026.

Boehringer Ingelheim

Boehringer Ingelheim, headquartered in Ingelheim am Rhein, Germany, sells Jardiance (empagliflozin) and the combinations Glyxambi and Jardiamet in Australia. In April 2025 the PBS widened Jardiance access, letting eligible high-risk patients start alongside metformin regardless of HbA1c and adding more than 115,000 eligible Australians. The co-payment cut of January 2026 further lowers patient cost for its SGLT2 range.

Other players operating in the Australia diabetes drugs market include Sanofi, Merck Sharp and Dohme, Sandoz, Pharmacor, and Servier, alongside generic suppliers, insulin biosimilar sponsors, parallel distributors and wholesalers supplying diabetes medicines to pharmacies, hospitals and online providers across Australia.

Key Insight

Competition rests on subsidy listings, patent position, supply reliability and prescriber habits rather than price alone, while generic entry gradually pressures established oral and insulin brands.